17,261 trials
Hepatitis C
Primary: Percentage of Participants With Complete Early Viral Response Below the Limit of Quantification (cEVR-LOQ) — 48.2; 61.1; 35.5; 74.3 percentage of participants
Central Vision Loss From Macular Diseases
Primary: Comparison of Changes in Visual Reading Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire — 1.29; 0.95…
Breast Cancer
Primary: Number of Patients With Pathologic Complete Response (pCR) — 6 patients
Hematologic Neoplasms
Primary: Number of Donors Treated With IV AMD3100 Who Required a Second Collection to Obtain the Minimum CD34/kg (2 X 106) Necessary for Allogeneic Stem Cell Transplant — 10…
Neuroblastoma
Primary: Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion — 4; 3 participants
Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR — 53 percentage of…
Prostate Cancer
Primary: Relapse-free Survival — 13; 10 months
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 101; 27 participants
Chronic Lymphocytic Leukemia
Primary: Complete Remission (CR) Rate of FCR3 in Treatment-naïve Participants With Chronic Lymphocytic Leukemia (CLL) at 6 Months — 75 Percentage of Participants
Lymphoma
Primary: Participant Response Rate According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 — 86.8; 91.6 Percentage of…
Esophageal Carcinoma
Primary: Median Recurrence Free Survival Time — 23.1 months
Carcinoma, Non-Small-Cell Lung
Primary: Phase 1: To Determine the Recommended Phase 2 Dose of the MM-121 + Erlotinib Combination Based Upon Either the Maximum Tolerated Dose (MTD) or the Maximum Feasible Dose…
Gastric Cancer
Primary: Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS) — 2.4; 6.3; 3.7; 5.2 percentage of participants
Lymphoma, T-cell, Peripheral
Primary: Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)…
Cardiac Allograft Vasculopathy
Primary: Insulin Levels Area Under Curve(AUC) — -47.7; 10.7 h*pmol/L